GPCR—is it down more for it's Diabetes effect than its Weight loss aspect?
IMO, the impetus for today’s selloff is the modest weight loss in both the T2D cohort (3-4% at 12 wks) and the obesity cohort (4.7% at 8 wks, placebo-adjusted).
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.